相似文献
1
Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.
Ann Rheum Dis. 2007 Jul;66(7):849-51. doi: 10.1136/ard.2007.069872.
2
Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Ann Rheum Dis. 2006 Jun;65(6):701-3. doi: 10.1136/ard.2005.049890.
3
Anti-TNF agents for rheumatoid arthritis.
Br J Clin Pharmacol. 2001 Mar;51(3):201-8. doi: 10.1046/j.1365-2125.2001.00321.x.
4
[Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
Med Clin (Barc). 2010 May 22;134(15):684-5. doi: 10.1016/j.medcli.2009.12.003. Epub 2010 Feb 21.
5
Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis.
Clin Rheumatol. 2007 Oct;26(10):1799-800. doi: 10.1007/s10067-007-0702-2. Epub 2007 Jul 24.
6
[Anti-TNF therapy in rheumatoid arthritis].
Nihon Rinsho Meneki Gakkai Kaishi. 2004 Feb;27(1):7-15. doi: 10.2177/jsci.27.7.
7
Which TNF inhibitor for rheumatoid arthritis?
Med Lett Drugs Ther. 2010 May 17;52(1338):38-9.
8
Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register).
Ann Rheum Dis. 2014 Jun;73(6):e31. doi: 10.1136/annrheumdis-2013-205011. Epub 2013 Dec 24.
9
Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.
Ann Rheum Dis. 2003 Dec;62(12):1195-8. doi: 10.1136/ard.2003.009589.
10
Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
Ann Rheum Dis. 2014 Jun;73(6):e32. doi: 10.1136/annrheumdis-2013-205037. Epub 2014 Mar 17.
引用本文的文献
1
Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
Rheumatology (Oxford). 2022 Oct 6;61(10):3939-3951. doi: 10.1093/rheumatology/keac048.
2
Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions.
Pharmacoeconomics. 2021 Jan;39(1):25-61. doi: 10.1007/s40273-020-00980-w. Epub 2020 Nov 26.
3
Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab.
Protein Sci. 2018 Jun;27(6):1038-1046. doi: 10.1002/pro.3407. Epub 2018 Apr 17.
4
Moderate to severe psoriasis treatment challenges through the era of biological drugs.
An Bras Dermatol. 2017 Sep-Oct;92(5):668-674. doi: 10.1590/abd1806-4841.20175603.
5
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.
Nat Rev Rheumatol. 2017 Nov 21;13(12):707-718. doi: 10.1038/nrrheum.2017.187.
6
[Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].
Z Rheumatol. 2015 Jun;74(5):406-13. doi: 10.1007/s00393-014-1533-6.
7
Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.
Expert Rev Vaccines. 2015 Jun;14(6):891-908. doi: 10.1586/14760584.2015.1026330. Epub 2015 Mar 18.
8
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi: 10.1186/1471-2474-15-14.
9
Pharmacogenetics and pharmacogenomics in rheumatology.
Immunol Res. 2013 Jul;56(2-3):325-33. doi: 10.1007/s12026-013-8405-z.
10
Genetics of rheumatoid arthritis - a comprehensive review.
Clin Rev Allergy Immunol. 2013 Oct;45(2):170-9. doi: 10.1007/s12016-012-8346-7.
本文引用的文献
1
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.
Ann Rheum Dis. 2007 Jul;66(7):893-9. doi: 10.1136/ard.2006.068304. Epub 2007 Apr 5.
2
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Ann Rheum Dis. 2007 Sep;66(9):1184-9. doi: 10.1136/ard.2006.054742. Epub 2007 Mar 27.
3
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
Ann Rheum Dis. 2007 Jul;66(7):921-6. doi: 10.1136/ard.2006.065615. Epub 2007 Feb 14.
4
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Arthritis Rheum. 2007 Jan;56(1):13-20. doi: 10.1002/art.22331.
5
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Arthritis Rheum. 2006 Dec;54(12):3782-9. doi: 10.1002/art.22214.
6
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Ann Rheum Dis. 2007 Feb;66(2):249-52. doi: 10.1136/ard.2006.058776. Epub 2006 Jul 12.
7
Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
Rheumatology (Oxford). 2006 Sep;45(9):1121-4. doi: 10.1093/rheumatology/kel054. Epub 2006 Mar 1.
8
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.
Arthritis Rheum. 2006 Mar;54(3):711-5. doi: 10.1002/art.21671.
9
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
Arthritis Res Ther. 2006;8(1):R29. doi: 10.1186/ar1881. Epub 2006 Jan 6.
10
The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
Clin Exp Rheumatol. 2005 Nov-Dec;23(6):795-800.
Zotero 插件